{"id":"https://openalex.org/W2990530712","doi":"https://doi.org/10.1182/blood-2019-129293","title":"Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib","display_name":"Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2990530712","doi":"https://doi.org/10.1182/blood-2019-129293","mag":"2990530712"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-129293","doi":"https://doi.org/10.1182/blood-2019-129293","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-129293","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074629157","display_name":"Bart Lee Scott","orcid":"https://orcid.org/0000-0001-9620-7839","observed_orcids":["https://orcid.org/0000-0001-9620-7839"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bart L. Scott","raw_affiliation_strings":["Fred Hutchinson Cancer Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029935496","display_name":"Mikl\u00f3s Egyed","orcid":"https://orcid.org/0000-0002-5513-5880","observed_orcids":["https://orcid.org/0000-0002-5513-5880"]},"institutions":[{"id":"https://openalex.org/I4210099897","display_name":"Somogy Megyei Kaposi M\u00f3r Oktat\u00f3 K\u00f3rh\u00e1z","ror":"https://ror.org/015mptv94","country_code":"HU","type":"healthcare","lineage":["https://openalex.org/I4210099897"]}],"countries":["HU"],"is_corresponding":false,"raw_author_name":"Miklos Egyed","raw_affiliation_strings":["Department of Internal Medicine/Hematology, Kaposi Mor Teaching Hospital, Kaposvar, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine/Hematology, Kaposi Mor Teaching Hospital, Kaposvar, Hungary","institution_ids":["https://openalex.org/I4210099897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I125671874","display_name":"National Health Service","ror":"https://ror.org/02wnqcb97","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I125671874","https://openalex.org/I1311074006"]},{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire N Harrison","raw_affiliation_strings":["Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I125671874","https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071257161","display_name":"Abdulraheem Yacoub","orcid":"https://orcid.org/0000-0001-5293-4620","observed_orcids":["https://orcid.org/0000-0001-5293-4620"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdulraheem Yacoub","raw_affiliation_strings":["Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046772202","display_name":"Alessandro Maria Vannucchi","orcid":"https://orcid.org/0000-0001-5755-0730","observed_orcids":["https://orcid.org/0000-0001-5755-0730"]},"institutions":[{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandro M. Vannucchi","raw_affiliation_strings":["CRIMM; Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Firenze, Italy","CRIMM"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CRIMM; Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Firenze, Italy","institution_ids":["https://openalex.org/I45084792"]},{"raw_affiliation_string":"CRIMM","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025797543","display_name":"Adam J. Mead","orcid":"https://orcid.org/0000-0001-8522-1002","observed_orcids":["https://orcid.org/0000-0001-8522-1002"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam J. Mead","raw_affiliation_strings":["University of Oxford, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford, Oxford, United Kingdom","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003941928","display_name":"Jennifer O\u2019Sullivan","orcid":"https://orcid.org/0000-0003-0502-7133","observed_orcids":["https://orcid.org/0000-0003-0502-7133"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jennifer O'Sullivan","raw_affiliation_strings":["University of Oxford, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford, Oxford, United Kingdom","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103255098","display_name":"Sarah A. Buckley","orcid":"https://orcid.org/0000-0002-7041-8328","observed_orcids":["https://orcid.org/0000-0002-7041-8328"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah A Buckley","raw_affiliation_strings":["CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082894654","display_name":"Diane R. Mould","orcid":"https://orcid.org/0000-0002-8908-0136","observed_orcids":["https://orcid.org/0000-0002-8908-0136"]},"institutions":[{"id":"https://openalex.org/I4210087078","display_name":"Phoenix Bioinformatics","ror":"https://ror.org/0018yg518","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210087078"]},{"id":"https://openalex.org/I4210133982","display_name":"Phoenix Medical Research","ror":"https://ror.org/03tm7cr19","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210133982"]},{"id":"https://openalex.org/I4210141028","display_name":"Panorama Research (United States)","ror":"https://ror.org/0434xpc34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210141028"]},{"id":"https://openalex.org/I4405265917","display_name":"Phoenix Geophysics (Canada)","ror":"https://ror.org/018k8gc58","country_code":"CA","type":"company","lineage":["https://openalex.org/I4405265917"]}],"countries":["CA","US"],"is_corresponding":false,"raw_author_name":"Diane R. Mould","raw_affiliation_strings":["Projections Research Inc, Phoenixville, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Projections Research Inc, Phoenixville, PA","institution_ids":["https://openalex.org/I4210087078","https://openalex.org/I4210133982","https://openalex.org/I4210141028","https://openalex.org/I4405265917"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008001331","display_name":"Shanthakumar Tyavanagimatt","orcid":"https://orcid.org/0009-0001-8519-3045","observed_orcids":["https://orcid.org/0009-0001-8519-3045"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shanthakumar Tyavanagimatt","raw_affiliation_strings":["CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060175597","display_name":"Jennifer A. Smith","orcid":"https://orcid.org/0000-0002-3575-5468","observed_orcids":["https://orcid.org/0000-0002-3575-5468","https://orcid.org/0000-0001-7717-2642"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Smith","raw_affiliation_strings":["CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072336042","display_name":"John O Mascarenhas","orcid":"https://orcid.org/0000-0002-8400-0483","observed_orcids":["https://orcid.org/0000-0002-8400-0483"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Mascarenhas","raw_affiliation_strings":["Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"667","last_page":"667"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pacritinib","display_name":"pacritinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9710000157356262},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.6769999861717224},{"id":"https://openalex.org/keywords/recommended-dose","display_name":"recommended dose","score":0.7269999980926514},{"id":"https://openalex.org/keywords/spleen-volume-reduction","display_name":"spleen volume reduction","score":0.8539999723434448},{"id":"https://openalex.org/keywords/total-symptom-score","display_name":"total symptom score","score":0.847000002861023},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6830000281333923},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9150000214576721},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.46399998664855957},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.5339999794960022},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9459999799728394},{"id":"https://openalex.org/keywords/calr-mutation","display_name":"CALR mutation","score":0.5450000166893005},{"id":"https://openalex.org/keywords/asxl1-mutation","display_name":"ASXL1 mutation","score":0.7549999952316284},{"id":"https://openalex.org/keywords/jak2-mutation","display_name":"JAK2 mutation","score":0.45399999618530273},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8865397572517395},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7560785412788391},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.6539010405540466},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5810363292694092},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.5623403191566467},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5260089635848999},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.513237714767456},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4952618181705475},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48548558354377747},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4718499183654785},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.46570783853530884},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.41352641582489014},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3614572286605835},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.17258843779563904},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-129293","doi":"https://doi.org/10.1182/blood-2019-129293","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-129293","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3107792394","https://openalex.org/W2587685665","https://openalex.org/W4405096213","https://openalex.org/W4296531060","https://openalex.org/W2560319905","https://openalex.org/W55085034","https://openalex.org/W2986406633","https://openalex.org/W4283399110","https://openalex.org/W4413781919","https://openalex.org/W4417004605"],"abstract_inverted_index":{"Background:":[0],"Pacritinib":[1],"(PAC),":[2],"an":[3,183,274,749,766,778,795,809,823,836,849,863,879,936,949,960,971,983,1038,1052,1074,1089],"oral":[4],"JAK2/IRAK":[5],"1":[6],"inhibitor,":[7],"has":[8,626],"demonstrated":[9,551,627],"clinical":[10,628],"benefit":[11,43,112,308],"in":[12,16,32,126,249,255,271,284,401,542,557,631,652,663],"myelofibrosis":[13],"(MF)":[14],"patients":[15,33,160,241,521,550,632,686],"two":[17],"prior":[18,188,704],"Phase":[19,28,194,200],"3":[20,201,457,682],"studies":[21,189],"(PERSIST-1,":[22],"PERSIST-2).":[23],"PAC203":[24,179,216,640],"is":[25,621,642],"a":[26,282,293,537,700],"randomized":[27,135],"2":[29,449,469],"dose-finding":[30],"study":[31,683],"with":[34,70,103,118,161,170,182,242,252,290,522,572,589,606,613,633,661,687],"MF":[35,76,440,688],"who":[36,77,108],"were":[37,78,134,180,247,301,324,347,443,587],"intolerant":[38,79,302],"of":[39,63,80,88,159,209,295,372,438,486,592,601,703,752,769,781,798,812,826,839,852,866,882,939,952,963,974,986,1041,1055,1077,1092],"or":[40,74,92,96,107,123,129,145,266,420,697,754,771,783,800,814,828,841,854,868,884,941,954,965,976,988,1043,1057,1079,1094],"failed":[41,110,306],"to":[42,58,111,131,137,204,303,307,369,696],"from":[44,113,178,187,309],"ruxolitinib.":[45],"Herein,":[46],"we":[47],"describe":[48],"the":[49,60,157,168,206,395,482,519,526,554,573],"results,":[50],"including":[51,326,685],"pharmacokinetic":[52],"and":[53,167,197,233,304,332,349,361,468,503,560,577,582,625,647,666,676,689],"pharmacodynamic":[54],"(PK/PD)":[55],"analyses,":[56],"used":[57],"identify":[59],"recommended":[61,207],"dose":[62,208,397],"PAC":[64,138,617,655,710],"for":[65,190,292],"further":[66],"study.":[67],"Methods:":[68],"Patients":[69,286],"DIPSS":[71],"intermediate-1,":[72],"-2,":[73],"high-risk":[75],"ruxolitinib":[81,114,291,602],"(treatment":[82,115],"\u226528":[83],"days":[84],"complicated":[85],"by":[86,150,644],"development":[87],"RBC":[89],"transfusion":[90],"requirement":[91],"grade":[93],"\u22653":[94,116],"anemia":[95],"thrombocytopenia,":[97],"hematoma,":[98,465],"and/or":[99],"hemorrhage":[100,375],"while":[101,311],"treated":[102,289],"<20":[104],"mg":[105,140,143,147,358,380,384,388,406,410,414,423,427,431,452,460,472,478,490,494,498,507,511,515,528,564,575,579,619,657,712],"BID)":[106],"had":[109,229,235,281,287,481,532,699],"months":[117],"<10%":[119],"spleen":[120,127,163,558,593,608,664],"volume":[121,164,559,594,609],"reduction":[122,165,662],"<30%":[124],"decrease":[125],"length":[128],"regrowth":[130],"these":[132],"parameters)":[133],"1:1:1":[136],"200":[139,357,451,477,527,563,618,656,711],"BID,":[141,144],"100":[142,146,383,387,409,413,426,430,459,471,493,497,510,514,574,578],"QD":[148,473,580],"stratified":[149],"baseline":[151],"platelet":[152,230,533],"count.":[153],"Efficacy":[154],"endpoints":[155],"included":[156,217],"proportion":[158,169],"\u226535%":[162,488,524,675],"(SVR)":[166],"\u226550%":[171,505],"total":[172],"symptom":[173,667],"score":[174],"(TSS)":[175],"reduction.":[176,595,615],"Results":[177],"pooled":[181],"integrated":[184],"data":[185],"set":[186],"population":[191,641],"PK":[192],"(prior":[193,199],"1-3":[195],"studies)":[196,202],"PK/PD":[198,545],"analysis":[203],"determine":[205],"PAC.":[210],"Data":[211],"cut":[212],"was":[213,225,269,566,603,659],"01-April-2019.":[214],"Results:":[215],"164":[218],"patients;":[219],"161":[220],"received":[221],"treatment.":[222],"Median":[223],"age":[224],"69":[226],"years;":[227,299],"43%":[228],"count":[231,637],"<50,000/mL":[232],"71%":[234],"hemoglobin":[236],"<10":[237],"g/dL.":[238],"In":[239,435],"105":[240],"molecular":[243,260],"data,":[244],"driver":[245],"mutations":[246,280],"present":[248,270],"99":[250],"(94%),":[251],"CALR":[253],"detected":[254],"only":[256],"9":[257],"(8.6%).":[258],"High-risk":[259],"type":[261],"(ASXL1,":[262],"EZH2,":[263],"SRSF2,":[264],"IDH1/2,":[265],"U2AF1":[267],"Q157)":[268],"41":[272],"(39%);":[273],"additional":[275],"5":[276,446,520],"(4.8%)":[277],"without":[278],"such":[279],"mutation":[283],"TP53.":[285],"been":[288],"median":[294],"1.4":[296],"(range:":[297],"0.6-3.0)":[298],"68%":[300],"73%":[305],"ruxolitinib,":[310],"47%":[312],"met":[313],"both":[314,351],"criteria.":[315],"The":[316,342,476,639],"most":[317,343],"common":[318,344],"treatment-emergent":[319],"non-hematologic":[320],"adverse":[321],"events":[322],"(AEs)":[323],"gastrointestinal,":[325],"diarrhea":[327],"(20.5%;":[328],"Grade":[329,335,373,392,402,418,445],"3:":[330,336],"3.1%)":[331],"nausea":[333],"(20%;":[334],"0.6%),":[337],"distributed":[338],"similarly":[339],"across":[340],"arms.":[341],"hematologic":[345],"AEs":[346],"thrombocytopenia":[348,635,691],"anemia,":[350],"occurring":[352],"at":[353,356,376,450,458,470,525,562],"higher":[354,370,377,584],"frequencies":[355],"BID":[359,453,461,479,529,565,576,620,658,713],"(32%":[360],"22%":[362],"respectively);":[363],"this":[364,436,543,653],"did":[365],"not,":[366],"however,":[367],"lead":[368],"rates":[371,485],"3/4":[374,403],"doses":[378],"(200":[379,405,422,489,506],"BID:":[381,385,407,411,424,428,491,495,508,512],"5.6%;":[382],"0%;":[386],"QD:":[389,415,432,499,516],"5.8%;":[390],"all":[391,417],"3).":[393],"Similarly,":[394],"highest":[396,483],"saw":[398],"no":[399],"excess":[400],"cardiac":[404],"3.7%;":[408,416],"7.3%;":[412],"3)":[419],"infectious":[421],"15%;":[425],"11%;":[429],"12%)":[433],"AEs.":[434],"cohort":[437],"advanced":[439],"patients,":[441],"there":[442],"7":[444],"(fatal)":[447],"AEs:":[448],"(sepsis,":[454,474],"subdural":[455,464],"hematoma),":[456],"(disease":[462],"progression,":[463],"heart":[466],"failure),":[467],"tuberculosis).":[475],"arm":[480],"observed":[484],"SVR":[487,523],"9.3%;":[492],"1.8%;":[496],"0.0%;":[500],"Figure":[501],"1)":[502],"TSS":[504,561,614,677],"7.4%;":[509],"5.5%;":[513],"5.8%).":[517],"Of":[518],"dose,":[530],"4":[531],"counts":[534],"<50,000/mL,":[535],"representing":[536],"17%":[538],"(4/24)":[539],"response":[540,672],"rate":[541],"population.":[544],"modeling":[546],"based":[547],"on":[548,748,765,777,794,808,822,835,848,862,878,935,948,959,970,982,1037,1051,1073,1088],"258":[549],"that":[552,553,570,583,692],"expected":[555],"improvement":[556],"substantially":[567],"greater":[568],"than":[569],"projected":[571],"regimens,":[581],"exposure":[585],"quartiles":[586],"associated":[588,605,660],"increased":[590],"probability":[591],"On":[596],"logistic":[597],"regression,":[598],"previous":[599],"use":[600],"significantly":[604],"less":[607],"reduction,":[610],"but":[611],"not":[612],"Conclusion:":[616],"generally":[622],"well":[623],"tolerated":[624],"activity,":[629],"particularly":[630],"severe":[634,690],"(platelet":[636],"<50,000/mL).":[638],"characterized":[643],"high-risk,":[645],"advanced,":[646],"heavily":[648],"pre-treated":[649],"disease;":[650],"even":[651],"group,":[654],"size":[665],"burden":[668],"using":[669],"stringent,":[670],"front-line":[671],"criteria":[673],"(SVR":[674],"\u226550%).":[678],"An":[679],"upcoming":[680],"phase":[681],"(PACIFICA),":[684],"are":[693],"either":[694],"na\u00efve":[695],"have":[698],"limited":[701],"duration":[702],"JAK2":[705],"inhibitor":[706],"therapy,":[707],"will":[708],"compare":[709],"vs.":[714],"physician's":[715],"choice.":[716],"Disclosures":[717],"Gerds:":[718],"Celgene":[719,762],"Corporation:":[720,763,775,845],"Consultancy,":[721,726,736,790,846,860,894,898,930,997,1007,1035,1049,1064,1071,1086],"Research":[722,727,733,737,740,744,786,804,817,831,874,895,899,903,907,910,913,916,1002,1008,1012,1046,1061,1065,1068,1082,1097,1100,1103,1106],"Funding;":[723,728,734,738,741,787,805,818,832,875,896,900,904,908,911,914,1009,1013,1047,1062,1066,1069,1083,1098,1101,1104],"CTI":[724,901,979,1084],"Biopharma:":[725,1085],"Pfizer:":[729,1014],"Consultancy;":[730,995],"Sierra":[731],"Oncology:":[732],"Incyte:":[735,876,912,957],"Roche:":[739,1063],"Imago":[742],"Biosciences:":[743],"Funding.":[745,917,1107],"Savona:AbbVie:":[746],"Membership":[747,764,776,793,807,821,834,847,861,877,934,947,958,969,981,1036,1050,1072,1087],"entity's":[750,767,779,796,810,824,837,850,864,880,937,950,961,972,984,1039,1053,1075,1090],"Board":[751,768,780,797,811,825,838,851,865,881,938,951,962,973,985,1040,1054,1076,1091],"Directors":[753,770,782,799,813,827,840,853,867,883,940,953,964,975,987,1042,1056,1078,1093],"advisory":[755,772,784,801,815,829,842,855,869,885,942,955,966,977,989,1044,1058,1080,1095],"committees;":[756,773,802,956,967,978,1059],"Boehringer":[757],"Ingelheim:":[758],"Patents":[759],"&":[760],"Royalties;":[761],"Incyte":[774],"committees,":[785,816,830,856,870,886,943,990,1045,1081,1096],"Karyopharm":[788],"Therapeutics:":[789,820,906],"Equity":[791,1019,1027,1032],"Ownership,":[792],"Sunesis:":[803],"Takeda:":[806],"TG":[819],"Selvita:":[833],"committees.":[843],"Scott:Celgene":[844],"Speakers":[857,871,887,890,919,922,925,931,944,991,1004],"Bureau;":[858,872,888,920,923,926,945,1005],"Alexion:":[859],"Novartis:":[873,909,996,1060],"Agios:":[889],"Bureau.":[891,932,992],"Talpaz:Imago":[892],"BioSciences:":[893],"Celgene:":[897,946,1006,1070],"BioPharma:":[902,980,1017,1022,1025,1030],"Samus":[905],"Constellation:":[915],"Harrison:Incyte:":[918],"Shire:":[921],"Gilead:":[924],"Promedior:":[927,1102],"Honoraria.":[928],"Yacoub:Incyte:":[929],"Vannucchi:Novartis:":[933],"Italfarmaco:":[968],"Mead:Bristol":[993],"Myers-Squibb:":[994],"Honoraria,":[998,1011],"Other:":[999],"Travel/accommodation":[1000],"expenses,":[1001],"Funding,":[1003],"CTI:":[1010],"Consultancy.":[1015,1023],"Buckley:CTI":[1016],"Employment,":[1018,1026,1031],"Ownership.":[1020,1028,1033],"Mould:CTI":[1021],"Tyavanagimatt:CTI":[1024],"Smith:CTI":[1029],"Mascarenhas:Incyte:":[1034],"Pharmaessentia:":[1048],"Merck:":[1067],"Janssen:":[1099],"Merus:":[1105]},"counts_by_year":[{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2019-12-05T00:00:00"}